A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation

Inclusion Criteria: * Signed informed consent of the subjects or the legal guardian. * Subjects and guardian are willing and able to cooperate to complete scheduled visits,treatment plans and laboratory tests and other procedures. * Diagnosed as chronic kidney disease. * Glomerular filtration rate (GFR) \<75ml/per min/1.73m2. * After the treatment and adjustment of hypertension, anemia, metabolic acidosis, malnutrition, renal osteopathy, hypothyroidism, etc.. * Chronological age: ≥2years and ≤14years. * Height Standard Deviation Score(HtSDS) ≤-2SD for chronological age. * Bone age: girls≤10 years; boys≤11years. * Pre-pubertal (Tanner Stage I ) patients. * No history of growth hormone treatment. Exclusion Criteria: * Subjects with abnormal liver functions. * Subjects positive for anti-HBc, HbsAg or HbeAg in Hepatitis B virus tests. * After adjustment heart function,Cardiac ejection fraction(EF) \<50%. * Subjects with highly allergic constitution or allergy to proteins or investigational product or its excipient. * Subjects with systemic chronic disease or general infection or mental disease. * Subjects with diabetes or impaired fasting glucose. * Subjects with tumor or potential tumor. * Subjects who are using glucocorticoid or immunosuppressant. * Other causes for growth retardation. * Inability to obtain accurate height measurements. * Subjects who took part in other clinical trials within 3 months. * Concomitant administration of other treatment that may have an effect on growth within 3 months. * Other conditions which are unsuitable for this study in the opinion of the investigator.